Evidence map›Paper›PMID 38796421›Full record

ArticleDiagnostic pathology2024

Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples.

James P Solomon, Carlos Munoz-Zuluaga, Cheyanne Slocum, Alicia Dillard, Lin Cong, Jiajing Wang, Neal Lindeman, Michael Kluk, Benjamin Liechty, David Pisapia and 2 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Ultra-Fast IntraoperativeInternational journal of molecular sciences · 2025
    Article
  3. Evaluation of anCancers · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

James P SolomonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Carlos Munoz-ZuluagaNewYork-Presbyterian Hospital, 525 East 68th Street Suite F-540, New York, NY, 10065, USA.
Cheyanne SlocumNewYork-Presbyterian Hospital, 525 East 68th Street Suite F-540, New York, NY, 10065, USA.
Alicia DillardNewYork-Presbyterian Hospital, 525 East 68th Street Suite F-540, New York, NY, 10065, USA.
Lin CongNewYork-Presbyterian Hospital, 525 East 68th Street Suite F-540, New York, NY, 10065, USA.
Jiajing WangDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Neal LindemanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Michael KlukDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Benjamin LiechtyDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
David PisapiaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Hanna RennertDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA.
Priya D VeluDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue Suite C-302, New York, NY, 10065, USA. prv9013@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IDH1 and IDH2 mutational status is a critical biomarker with diagnostic, prognostic, and treatment implications in glioma. Although IDH1 p.R132H-specific immunohistochemistry is available, it is unable to identify other mutations in IDH1/2. Next-generation sequencing can accurately determine IDH1/2 mutational status but suffers from long turnaround time when urgent treatment planning and initiation is medically necessary. The Idylla assay can detect IDH1/2 mutational status from unstained formalin-fixed paraffin-embedded (FFPE) slides in as little as a few hours. In a clinical validation, we demonstrate clinical accuracy of 97% compared to next-generation sequencing. Sensitivity studies demonstrated a limit of detection of 2.5-5% variant allele frequency, even at DNA inputs below the manufacturer's recommended threshold. Overall, the assay is an effective and accurate method for rapid determination of IDH1/2 mutational status.

Indexed as

Brain NeoplasmsGliomaIsocitrate DehydrogenaseMutationBiomarkers, TumorDNA Mutational AnalysisFormaldehydeHigh-Throughput Nucleotide SequencingHumansParaffin EmbeddingReproducibility of ResultsTissue FixationBiomarkers, TumorFormaldehydeIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseGliomaIDH1IDH2Idylla

Identifiers

PMID38796421
PMCPMC11128120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.